eClinical Technology and Industy News

Sionna Therapeutics Announces Advancement of Cystic Fibrosis Pipeline Programs and Presentation at J.P. Morgan 41st Annual Healthcare Conference


– Enrolling Phase 1 study of lead NBD1 modulator, SION-638, following IND clearance from the FDA; data expected in the second half of 2023 –

– SION-109, targeting complementary mechanism ICL4, on-track for IND submission in the first half of 2023 –

– Three additional development candidates nominated for progression including two Series 2 NBD1 modulators –

Excerpt from the Press Release:

BOSTON, Jan. 5, 2023 /PRNewswire/ — Sionna Therapeutics, a life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF), today announced advancement of the company’s preclinical and clinical development programs for novel small molecules designed to target the first nucleotide-binding domain (NBD1) of the cystic fibrosis transmembrane conductance regulator (CFTR) protein and complementary mechanisms. Mike Cloonan, President and Chief Executive Officer of Sionna, will provide an overview of the Company’s progress and pipeline updates at the J.P. Morgan 41st Annual Healthcare Conference on January 10, 2023, at 8:00 AM PST in San Francisco.

“We formed Sionna to deliver therapies that could be transformational for people living with CF, and data continue to reinforce the opportunity to improve CFTR function for modulator-eligible patients,” said Mr. Cloonan. “Modulators that provide normal CFTR function could have a significant impact on clinical outcomes for people with CF. We are progressing with our lead candidate and multiple Series 2 modulators targeting NBD1, as well as complementary mechanisms, to target multiple domains of CFTR. This strategy will support future development of proprietary combination treatments with the potential to achieve full CFTR correction.”

As previously announced, the Investigational New Drug application (IND) for SION-638, the company’s lead novel small molecule targeting the NBD1 domain, has cleared. The first subjects have been dosed in a Phase 1 study to evaluate the safety and pharmacokinetics of SION-638.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives